Gotham Asset Management’s ImmunityBio IBRX Stock Holding History

Gotham Asset Management’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.54M	Buy	175,564 +163,427	+1,347%	+$1.24M	﹤0.01%	1233
2026 Q1	$93.1K	Buy	+12,137	New	+$83.1K	﹤0.01%	1725
2025 Q3	–	Sell	-16,224	Closed	-$42.8K	–	1749
2025 Q2	$42.8K	Sell	16,224 -28,781	-64%	-$77.4K	﹤0.01%	1649
2025 Q1	$135K	Buy	+45,005	New	+$136K	﹤0.01%	1494
2024 Q3	–	Sell	-14,594	Closed	-$92.2K	–	1471
2024 Q2	$92.2K	Sell	14,594 -17,932	-55%	-$118K	﹤0.01%	1384
2024 Q1	$175K	Buy	32,526 +21,738	+202%	+$98.4K	﹤0.01%	1299
2023 Q4	$54.2K	Buy	+10,788	New	+$33.9K	﹤0.01%	1308
2020 Q3	–	Sell	-27,855	Closed	-$342K	–	1083
2020 Q2	$342K	Buy	+27,855	New	+$157K	0.01%	834
2017 Q3	–	Sell	-13,766	Closed	-$104K	–	969
2017 Q2	$104K	Buy	+13,766	New	+$59.5K	﹤0.01%	929

Other funds holding IBRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Gotham Asset Management's IBRX Position: Q2 2026 in Review

Gotham Asset Management increased its ImmunityBio (IBRX) stake by 1,347% in Q2 2026, buying an estimated $1.24M and bringing the position to 175,564 shares worth $1.54M. The position accounts for ﹤0.01% of the portfolio, ranked #1233.

Gotham Asset Management first reported a position in IBRX in Q2 2017 and has held it in 9 quarters since. 404 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

Gotham Asset Management held 175,564 shares of ImmunityBio worth $1.54M as of Q2 2026.
Gotham Asset Management bought 163,427 ImmunityBio shares in Q2 2026, an estimated $1.24M.
ImmunityBio made up ﹤0.01% of Gotham Asset Management's portfolio in Q2 2026, its #1233 holding.
Gotham Asset Management first reported a position in ImmunityBio in Q2 2017 and has held it in 9 quarters since.
404 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Gotham Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.